Keywords: Pfizer, Protalix, Taliglucerase, Gaucher disease, Europe filing
Pfizer and Protalix file for European approval of Gaucher drug taliglucerase
Article | 30 November 2010
Global pharmaceutical behemoth Pfizer (NYSE: PFE) and Israel’s Protalix BioTherapeutics, (TASE: PLX) have submitted a Marketing Authorization Application ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
